Cargando…
Short-term cost-effectiveness analysis of tirzepatide for the treatment of type 2 diabetes in the United States
BACKGROUND: Tirzepatide is a novel once-a-week dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist that is used as an addition to diet and exercise to improve blood glucose in adults with type 2 diabetes. It is the first dual glucagon-like peptide-1 and glu...
Autores principales: | Zhang, Xiaotong, McAdam Marx, Carrie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388019/ https://www.ncbi.nlm.nih.gov/pubmed/36840958 http://dx.doi.org/10.18553/jmcp.2023.29.3.276 |
Ejemplares similares
-
Short-term cost-effectiveness of oral semaglutide for the treatment of type 2 diabetes mellitus in the United States
por: Cui, Jiayu, et al.
Publicado: (2021) -
Tirzepatide for type 2 diabetes
por: Anderson, Sarah L, et al.
Publicado: (2023) -
Treatment of Type 1 and Type 2 Diabetes Mellitus with Insulin Detemir, a Long-Acting Insulin Analog
por: Young, Jason R., et al.
Publicado: (2010) -
Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective
por: De Block, Christophe, et al.
Publicado: (2022) -
Cost per Patient Achieving Treatment Targets and Number Needed to Treat with Tirzepatide Versus Semaglutide 1 mg in Patients with Type 2 Diabetes in the United States
por: Mody, Reema R., et al.
Publicado: (2023)